title: [Cutaneous adverse drug reactions: enhanced imputation score by skin testing].
abstract: BACKGROUND
  A careful diagnosis and the identification of the causative drug after a cutaneous adverse reaction can avoid relapses. Skin tests facilitate the identification of the causative molecule by producing a hypersensitivity reaction at the application site. Adverse drug reactions are reported to Pharmacovigilance Centres who determine the imputation score of the suspected drugs. The aim of this study was to assess to what extent skin testing after a suspected allergic drug reaction can be helpful to identify the causative drug and whether an impact on the final imputation score could be evidenced.
  
  
  METHODS
  A 18-month prospective study was performed. All patients with a history of cutaneous adverse drug reaction of suspected immunoallergic origin were included provided skin tests could be performed within 6 to 12 weeks after the adverse drug reaction. The imputation score was determined using the French imputation method prior to and after skin testing.
  
  
  RESULTS
  Thirthy-nine patients were included in the study. Positive skin tests were observed in 11 of 20 patients with a C2S2 (I2: plausible) initial imputation score and in 6 of 15 patients with a C2S1 (I1: doubtful) initial imputation score. One patient with a C1S1 (I1: doubtful) initial imputation score had positive skin tests.
  
  
  CONCLUSIONS
  The results of skin tests helped change the imputation score of the suspected drug in 18 patients out of 39. In 55 p. 100 of cases, the imputation score was increased from C2S2 (I2) to C2S3 (I3: likely) and from C2S1 (I1) to C2S3 (I3) in 40 p. 100 of cases. The increase in imputation scores was helpful to improve warning signals after an immunoallergic reaction. Skin tests led to a more accurate diagnosis in 50 p. 100 of cases. Thus, more adequate advices for further drug treatment were possible, particularly in avoiding the irrelevant prohibition of innocent drugs.
authors.affiliation: Centre Antipoison, Centre de Pharmacovigilance, Hôpital Edouard Herriot, Lyon. kasty@free.fr
authors.forename: G
authors.initials: G
authors.lastname: Choquet-Kastylevsky
authors.forename: T
authors.initials: T
authors.lastname: Vial
authors.forename: N
authors.initials: N
authors.lastname: Santolaria
authors.forename: A
authors.initials: A
authors.lastname: Nageotte
authors.forename: M
authors.initials: M
authors.lastname: Faure
authors.forename: A
authors.initials: A
authors.lastname: Claudy
authors.forename: J
authors.initials: J
authors.lastname: Descotes
mesh_terms: D000293:Adolescent; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000368:Aged; D000369:Aged, 80 and over; D003875:Drug Eruptions / Q000145:classification / Q000175:diagnosis* / Q000209:etiology*; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D017891:Pharmacoepidemiology; D011446:Prospective Studies; D012008:Recurrence; D012720:Severity of Illness Index; D012882:Skin Tests / Q000379:methods* / Q000592:standards*; D013997:Time Factors